NON SMALL CELL LUNG CANCER METASTATIC

This study is for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the brain. Researchers want to see if adding a precise, one-time radiation treatment (SRS) to the standard drug osimertinib is better than the drug alone at controlling brain tumor…

This study looks at whether adding a precise radiation dose to liver tumors can make standard immunotherapy work better for people with stage IV non-small cell lung cancer. About 68 adults whose cancer has spread to the liver will either get standard drug therapy alone or standar…

This study compares an experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive one of the two drugs by …

This phase 2 trial tests whether combining two targeted drugs—lazertinib and tepotinib—can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer whose disease has worsened after initial lazertinib treatment due to MET gene changes. About 47 participants wil…

This study tests a new drug called OM-RCA-01 in people with several types of cancer that have spread to other parts of the body and have a specific marker (FGFR1). The drug is an antibody given through a vein every two weeks. The main goals are to find a safe dose and see if it c…

This early-stage trial tests a treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to attack the cancer…

This study tests whether using a protein-based test to guide treatment choices can help people with advanced non-small cell lung cancer live longer without their cancer getting worse. About 56 adults with stage IIIC or IV lung cancer will be randomly assigned to either standard t…

This study tests whether regular blood tests (liquid biopsies) can better monitor treatment in 350 people with advanced non-small cell lung cancer who are receiving immunotherapy. The goal is to see if this approach reduces the number of ineffective treatments and unnecessary sid…

This study tests whether a simple blood test (ctDNA) can help doctors decide if adding chemotherapy to the immunotherapy drug cemiplimab works better for advanced lung cancer. About 63 people with stage IV or stage IIIB/C non-small cell lung cancer that hasn't been treated before…

This study looks at whether giving a brain MRI to people newly diagnosed with stage IV non-small cell lung cancer (who have no brain symptoms) provides useful information for their doctors. About 100 participants will get an MRI, and doctors will fill out questionnaires to see if…

This observational study is following 100 adults with metastatic non-small cell lung cancer who have certain EGFR mutations and are receiving amivantamab plus platinum-based chemotherapy through an early access program. Researchers want to see how long the treatment keeps the can…

This study is collecting real-world data from 300 patients in Italy who are receiving a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment for advanced non-small cell lung cancer. The goal is to see how long patients live …